Loading
Life sciences · Journal article
Frontiers in Oncology · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Urachal adenocarcinoma is a rare malignancy without prospective treatment trials. Management of metastatic disease is typically extrapolated from colorectal cancer (CRC) due to histologic and molecular similarities. An 80-year-old woman with metastatic urachal adenocarcinoma received sequential CRC-based therapy including first-line CAPOX plus bevacizumab, second-line FOLFIRI plus bevacizumab, third-line trifluridine/tipiracil plus bevacizumab, in addition to brief administration of regorafenib and fruquintinib in the fourth- and fifth-line setting. Oxaliplatin was discontinued after one cycle due to worsening of vision on a background of pre-existing retinopathy. The longest disease control (time to progression ~11 months) occurred with trifluridine/tipiracil plus bevacizumab. To our knowledge, this represents the first report describing use of this combination in the third-line setting for metastatic urachal carcinoma. Overall survival was 27 months. This case is hypothesis-generating for the use of modern CRC-based therapies, including anti-VEGF–containing combinations.